Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01878565

The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion

The Treatment With Nucleoside Analogues in Combination With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion: a Phase I/II, Single-blind, Randomized, GM-CSF-controlled Trial

Sponsor: Beijing 302 Hospital

Conditions Chronic Hepatitis B

Interventions Drug GM-CSF control

Updated 5 times since 2017 Last updated: Jul 23, 2013 Started: Jun 30, 2013 Primary completion: Dec 31, 2014 Completion: Jul 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Chronic Hepatitis B, this trial is ongoing. The trial is conducted by Beijing 302 Hospital and has accumulated 5 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing 302 Hospital

Data source: Beijing 302 Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China